drugset
Drugs / F/TAF
last change 3 days ago re-read 2 minutes ago

F/TAF

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT07658976 Background Sep 2026 → Sep 2029 expected HIV infectious disease HIV Prevention Trials Network Not yet recruiting No outcome recorded

Press releases naming this drug 5 releases

DateIssuerRelease
2016-02-23 Gilead Sciences Gilead Announces Results From First Study to Evaluate Switching to F/TAF-Based Regimens from Truvada® (F/TDF)-Based Regimens gilead.com ↗
2015-09-02 Gilead Sciences Gilead’s Investigational Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide (F/TAF) Meets Primary 48-Week Objective in Phase 3 Study gilead.com ↗
2015-08-20 Gilead Sciences European Medicines Agency Validates Gilead’s Marketing Application for Single Tablet Regimen Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF) for HIV Treatment gilead.com ↗
2015-07-21 Gilead Sciences Gilead Announces Phase 3 Results From the First Study to Evaluate Switching From TDF-Based Regimens to a TAF-Based Regimen Containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide (E/C/F/TAF) gilead.com ↗
2015-07-01 Gilead Sciences Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen for HIV Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF) gilead.com ↗

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as F/TAF ClinicalTrials.gov intervention name — accepted as the source's own label NCT07658976 ↗